New EMCDDA report underlines need to scale up drug services in prisons

Current insights and future challenges on drugs and prison in Europe are explored today in a major new study published by the EU drugs agency (EMCDDA)(1). Released on the eve of International day against drug abuse and illicit trafficking, the report, Prison and drugs in Europe: current and future challenges, takes an in-depth look at a wide range of issues in the prison setting, including drug use and harms, health and social responses and drug supply. 25.06.2021  International Day against Drug Abuse and Illicit Trafficking — 26 June
Read more

Council approves EU Drugs Action Plan 2021–2025

The Council of the EU (Foreign Affairs) approved on 21 June the EU Drugs Action Plan for 2021–2025. The new plan presents the concrete actions needed to achieve the priorities of the EU Drugs Strategy, adopted in December 2020 (1). 22.06.2021 
Read more

A year in review: General Report of Activities 2020 published today

Resilience, agility and innovation are among the recurring themes in the latest EMCDDA General Report of Activities, released today. The annual publication — presenting key achievements and governance — relates how the EMCDDA executed its work programme in 2020, a special year marking its 25 years of monitoring, but also the arrival of COVID-19. 15.06.2021 
Read more

Speech delivered by Laura d’Arrigo, Chair of the EMCDDA Management Board, on the launch of the European Drug Report 2021

Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way in which we live. Countries in Europe, and around the world, have had to introduce unprecedented measures to protect public health. All aspects of the drug phenomenon in Europe — including production, trafficking, distribution and use — have also been affected by the pandemic. The European Drug Report 2021 this year provides the latest overview of these developments. 09.06.2021 
Read more

European drug market proves resilient to COVID-19 disruption

Today, the EU drugs agency (EMCDDA) publishes its European Drug Report 2021: Trends and Developments, the latest annual review of the drug situation in Europe (1). Based on data from 29 countries (EU 27, Turkey and Norway), the report offers new insights into the health and security implications of a complex and evolving drugs problem and of a drug market resilient to COVID-19 disruption. 09.06.2021  European Drug Report 2021: Highlights
Read more

New report highlights public health risks and increasing availability of ‘designer benzodiazepines’ in Europe

New benzodiazepines, which are not controlled by international drug laws, come under the spotlight today in a new report released by the EU drugs agency (EMCDDA) (1). Often marketed as ‘designer benzodiazepines’, these substances are sold as ‘legal’ replacements for controlled benzodiazepines and are becoming increasingly available in Europe. 09.06.2021  New benzodiazepines under the spotlight
Read more